Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Bhap Der: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Bhap Der - General Information

A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.

 

Pharmacology of Bhap Der

Bhap Der is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Bhap Der binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Bhap Der does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Bhap Der.

 

Bhap Der for patients

Patients should be informed that RESCRIPTOR is not a cure for HIV-1
infection and that they may continue to acquire illnesses associated
with HIV-1 infection, including opportunistic infections. Treatment
with RESCRIPTOR has not been shown to reduce the incidence or frequency
of such illnesses, and patients should be advised to remain under the
care of a physician when using RESCRIPTOR. Patients should be advised
that the long-term effects of treatment with RESCRIPTOR are unknown at
this time. They should be advised that the use of RESCRIPTOR has not been
shown to reduce the risk of transmission of HIV-1.

 

Bhap Der Interactions

Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir,
Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin,
Ritanovir, Saquinavir.

 

Bhap Der Contraindications

RESCRIPTOR Tablets are contraindicated in patients with previously
demonstrated clinically significant hypersensitivity to any of the
components of the formulation.

 

Additional information about Bhap Der

Bhap Der Indication: For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted Mechanism Of Action: Bhap Der binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site. Drug Interactions: Alprazolam The antiviral agent increases the effect and toxicity of benzodiazepine Amprenavir Decreased levels of delavirdine with increased levels of amprenavir Astemizole Increased risk of cardiotoxicity and arrhythmias Atorvastatin The NNRT inhibitor increases the effect and toxicity of the statin Carbamazepine The anticonvulsant decreases the effect of delavirdine Cisapride Increased risk of cardiotoxicity adn arrhythmias Dihydroergotamine The antiretroviral agent may increase the ergot derivative toxicity Dihydroergotoxine The antiretroviral agent may increase the ergot derivative toxicity Ergonovine The antiretroviral agent may increase the ergot derivative toxicity Ergotamine The antiretroviral agent may increase the ergot derivative toxicity Fosamprenavir Decreased levels of delavirdine with increased levels of amprenavir Fosphenytoin The anticonvulsant decreases the effect of delavirdine Indinavir Increases the effect of indinavir Lovastatin The NNRT inhibitor increases the effect and toxicity of the statin Methylergonovine The antiretroviral agent may increase the ergot derivative toxicity Methylphenobarbital The anticonvulsant decreases the effect of delavirdine Methysergide The antiretroviral agent may increase the ergot derivative toxicity Midazolam The antiviral agent increases the effect and toxicity of benzodiazepine Phenobarbital The anticonvulsant decreases the effect of delavirdine Phenytoin The anticonvulsant decreases the effect of delavirdine Quinupristin This combination presents an increased risk of toxicity Rifabutin Rifabutin decreases the effect of delavirdine Rifampin Rifampin decreases the effect of delavirdine Ritonavir Increases the effect of ritonavir Saquinavir Increases the effect of saquinavir and hepatic toxicity Simvastatin The NNRT inhibitor increases the effect and toxicity of the statin St. John's Wort St. John's Wort decreases the antiretroviral effect Terfenadine Increased risk of cardiotoxicity and arrhythmias Triazolam The antiviral agent increases the effect and toxicity of benzodiazepine Aluminium The antiacid decreases the effect of delavirdine Bismuth The antiacid decreases the effect of delavirdine Calcium The antiacid decreases the effect of delavirdine Magnesium oxide The antiacid decreases the effect of delavirdine Magnesium The antiacid decreases the effect of delavirdine Food Interactions: Take without regard to meals. Generic Name: Delavirdine Synonyms: DLV; SPP Drug Category: Anti-HIV Agents; Nonnucleoside Reverse Transcriptase Inhibitors Drug Type: Small Molecule; Approved Other Brand Names containing Delavirdine: Bhap Der; Rescriptor; Absorption: Rapidly absorbed Toxicity (Overdose): Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician. Protein Binding: 98% Biotransformation: Hepatic Half Life: 5.8 hours Dosage Forms of Bhap Der: Tablet Oral Chemical IUPAC Name: N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide Chemical Formula: C22H28N6O3S Delavirdine on Wikipedia: https://en.wikipedia.org/wiki/Delavirdine Organisms Affected: Human Immunodeficiency Virus